高灵敏度抗苗勒管激素检测监测乳腺癌化疗期间卵巢储备动态
前瞻性队列研究纳入145例绝经前乳腺癌患者,其中83例接受化疗、62例未化疗,采用超灵敏抗苗勒管激素(UD-AMH)检测(检测限0.13 pg/ml)从治疗前随访至化疗后12个月。结果显示化疗后12个月30%患者发生早发性卵巢功能不全(POI),治疗前及化疗结束时AMH水平是POI的强预测因子。
要点
- UD-AMH检测可在所有样本中定量AMH,灵敏度较传统方法高100倍。
- 化疗后12个月30%的乳腺癌患者发生POI。
- 化疗结束时AMH预测POI的AUC为0.89,优于治疗前AMH的AUC 0.86。
核心结论
- 治疗前和化疗结束时通过UD-AMH检测的低AMH水平是化疗后12个月发生POI的强预测因子。
研究设计与样本
- 前瞻性队列研究,共纳入145例绝经前乳腺癌患者(18-46岁),其中83例计划接受化疗、62例未化疗,随访从治疗前至化疗后12个月。
主要发现
- 化疗后12个月30%的患者发生POI。
- 非POI组治疗前AMH中位数显著高于POI组(5425 pg/ml vs 1103 pg/ml,P < 0.001)。
- 非POI组化疗结束时AMH中位数显著高于POI组(127 pg/ml vs 10 pg/ml,P < 0.001)。
- 治疗前AMH预测POI的AUC为0.86(敏感性67%,特异性95%)。
- 化疗结束时AMH预测POI的AUC为0.89(敏感性81%,特异性93%)。
关键数值与推荐
- POI定义为月经稀发或闭经伴促卵泡激素(FSH)水平 >25 mIU/ml。
- UD-AMH检测限为0.13 pg/ml,灵敏度较传统方法高100倍。
临床怎么用
- UD-AMH检测可用于早期预测化疗后POI,指导个体化治疗决策和生育力保存策略。
局限性
- 单中心研究,样本量因COVID-19疫情而 attrition。
- 研究仅关注化疗后1个月内的激素动态,缺乏风险组的长期临床生育结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does an ultra-sensitive anti-Müllerian hormone (UD-AMH) assay enhance the accuracy of ovarian dysfunction assessment in premenopausal women with breast cancer (PBC) during and after chemotherapy? SUMMARY ANSWER: Low AMH levels at pre-treatment and end-of-chemotherapy, measured by the UD-AMH assay, are strong predictors for the development of premature ovarian insufficiency (POI) at 12 months post-chemotherapy. WHAT IS KNOWN ALREADY: Anti-Müllerian hormone (AMH) is a recognized biomarker for assessing ovarian reserve and serves as an early indicator of ovarian dysfunction in female cancer patients. However, post-chemotherapy AMH levels frequently fall below detectable limits of conventional assays, hindering rapid and accurate evaluation of residual ovarian reserve. STUDY DESIGN, SIZE, DURATION: Prospective cohort study; 145 total subjects enrolled; follow-up conducted from pre-treatment through 12 months post-chemotherapy. PARTICIPANTS/MATERIALS, SETTING, METHODS: Premenopausal women (aged 18-46 years) with breast cancer recruited at diagnosis; 83 scheduled to receive chemotherapy and 62 who did not. Serum samples were collected pre-treatment (T0), after each chemotherapy cycle, at end-of-chemotherapy (T1), 3 (T2), 6 (T3), and 12 (T4) months post-chemotherapy. AMH levels were quantified using the UD-AMH assay (detection limit 0.13 pg/ml, offering 100-fold higher sensitivity than conventional methods). POI was defined as oligo/amenorrhea with follicle-stimulating hormone (FSH) levels >25 mIU/ml. MAIN RESULTS AND THE ROLE OF CHANCE: AMH was quantifiable in all samples by using the UD-AMH assay. At T4, 30% of PBC exhibited POI. AMH levels at T0 were significantly higher in the non-POI group compared to the POI group (median 5425 pg/ml vs 1103 pg/ml, P < 0.001), as were levels at T1 (median 127 pg/ml vs 10 pg/ml, P < 0.001). T0 AMH predicted POI with an AUC of 0.86 (sensitivity 67%, specificity 95%), while T1 AMH showed superior predictive value with an AUC of 0.89 (sensitivity 81%, specificity 93%). LIMITATIONS, REASONS FOR CAUTION: This trial was a single-center study with sample size attrition due to the COVID-19 pandemic. Additionally, the study focused on hormonal dynamics up to 1 months post-chemotherapy, lacking long-term data on clinical fertility outcomes in the identified risk groups. WIDER IMPLICATIONS OF THE FINDINGS: The application of the UD-AMH assay enables early prediction of POI and offers a valuable tool to guide personalized treatment decisions and fertility preservation strategies in young female cancer patients. FUNDING: This work was supported by the National Key Research and Development Program of China (2023YFB3210301), National Natural Science Foundation of China (82271664), Shanghai Municipal Council for Science and Technology (20JC1412100), the Shanghai Municipal Health Commission (202240345), the interdisciplinary program of Shanghai Jiao Tong University (YG2022ZD028), and the Shanghai Key Laboratory of Embryo Original Diseases (Shelab2022ZD01). DISCLOSURES: R.A.A. has received research support from Roche Diagnostics; all other authors declare no competing interests. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT04767607.
引用
- Kuang X, Ji M, Tang Y, et al. Monitoring ovarian reserve dynamics via a high-sensitivity anti-Müllerian hormone assay in premenopausal breast cancer patients undergoing chemotherapy. Hum Reprod. 2026. PMID: 42664366. doi:10.1093/humrep/deag136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。